Core Insights - The recent conference in Suzhou focused on advancements in the diagnosis and treatment of Acute Lymphoblastic Leukemia (ALL), aiming to enhance the standard of care in Jiangsu Province [1][2] - ALL accounts for 30% to 40% of acute leukemia cases, primarily affecting adults aged 30 to 40, with poor prognosis for patients over 40 and those with relapsed or refractory cases [1] Group 1: Current Status and Challenges - Significant improvements in survival rates for ALL patients have been observed due to advancements in treatment technologies, including bispecific antibodies and CAR T-cell therapy [2] - Despite these advancements, there are still unmet needs in clinical diagnosis and treatment, particularly in grassroots medical institutions, leading to a lack of standardized care for many patients [2] Group 2: Initiatives and Future Directions - The Jiangsu ALL Working Group has been established to explore standardized treatment pathways and improve overall care quality, focusing on the development of clinical pathways for ph+/ph- B-ALL [2] - The group aims to enhance regional diagnostic and treatment levels through regular academic exchanges, case consultations, and research initiatives, ultimately striving for a uniform standard of care across the province [2][3] - Future efforts will include optimizing standardized treatment pathways and promoting the "Jiangsu experience" nationwide to improve ALL care for more patients [3]